Patents by Inventor Mark R. Player

Mark R. Player has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS
    Publication number: 20240109910
    Abstract: The present invention is related to compounds of formula (I) and compounds of formula (II) and pharmaceutical composition thereof, useful as agonists of the CB1 and/or CB2 receptor(s).
    Type: Application
    Filed: October 9, 2020
    Publication date: April 4, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: SANATH K MEEGALLA, Mark R. Player
  • Cyclohexyl GPR40 agonists for the treatment of type II diabetes
    Patent number: 10988433
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: wherein R1B, WB, LB, , and GB are defined herein.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 27, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, James C. Lanter, Sanath K. Meegalla, Mark R. Player
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10662170
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20200039914
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: wherein R1B, WB, LB, , and GB are defined herein.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 6, 2020
    Inventors: Hui Huang, James C. Lanter, Sanath K. Meegalla, Mark R. Player
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20190062300
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 28, 2019
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10131648
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 20, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10106553
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U1, U2, U3, R1, R2, Z, and W are defined herein.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: October 23, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sanath Meegalla, Mark R. Player, Hui Huang, Michael P. Winters
  • GPR40 agonists for the treatment of type II diabetes
    Patent number: 9920040
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: March 20, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • GPR40 agonists for the treatment of type II diabetes
    Patent number: 9908873
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (II) as follows: wherein R1B, R2B, R4B, WB, XB, YB, and GB, are defined herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: March 6, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • GPR40 agonists for the treatment of type II diabetes
    Patent number: 9856245
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III) as follows: wherein R1C, R2C, R4C, WC, YC, ZC, and GC, are defined herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170362196
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 21, 2017
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 9790198
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 17, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170291908
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U1, U2, U3, R1, R2, Z, and W are defined herein.
    Type: Application
    Filed: April 11, 2017
    Publication date: October 12, 2017
    Inventors: Sanath Meegalla, Mark R. Player, Hui Huang, Michael P. Winters
  • Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators
    Patent number: 9718820
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 1, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Substituted pyrazines as GPR40 agonists
    Patent number: 9688642
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and R2 are defined herein.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 27, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sanath Meegalla, Hui Huang, Mark R. Player
  • GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170044146
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 16, 2017
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170044148
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III) as follows: wherein R1C, R2C, R4C, WC, YC, ZC, and GC, are defined herein.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 16, 2017
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170044147
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (II) as follows: wherein R1B, R2B, R4B, WB, XB, YB, and GB, are defined herein.
    Type: Application
    Filed: August 4, 2016
    Publication date: February 16, 2017
    Inventors: Hui Huang, Sanath Meegalla, Mark R. Player
  • SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    Publication number: 20160304518
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
    Patent number: 9409915
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: August 9, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum